Your English writing platform
Discover LudwigExact(2)
Although the RECIST guidelines were based on the model proposed by James et al (1999), they consider a 20% sum diameter increase to be enough for progression.
Although the volume relationship between the WHO criteria for progressive disease (25% sum product increase; 40% volume size) and RECIST (20% sum diameter increase; 73% volume increase) was not the same, in our study there was a complete concordance in all the patients who progressed due to an increase in measurement of pre-existing lesions.
Similar(58)
Thus, it is possible to define a partial response (PR), corresponding to at least a 30% decrease in the sum of diameters of target tumours, taking as reference the baseline sum diameters [2].
at least 30% decrease in the sum of diameters of target lesions, taking a reference the baseline sum diameters.
Partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, using the baseline sum diameters as a reference.
9 "Partial response" is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
The disappearance of all target lesions was considered a complete response (CR) while partial response (PR) was defined as a decrease in the sum of diameters of target lesions of at least a 30%, taking as reference the baseline sum diameters.
8, 9 According to RECIST, "stable disease" is defined as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters while on study.
The modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria for hepatocellular cancer, in which disease assessments are based on the sum of the diameters of viable disease rather than on the sum of the total diameters of the target lesions, were published after this study had begun [ 25].
We therefore analysed the association between the Response Evaluation Criteria in Solid Tumors (RECIST) baseline sum longest diameter (BSLD) and clinical outcomes in a recent phase 3 Eastern Cooperative Oncology Group (ECOG) trial for advanced NSCLC, E4599.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com